The pathophysiology associated with major burns is complex and subject to a state of flux. The combination of ␤-lactamase inhibitors with powerful penicillins is an interesting and an attractive potential solution to the emergence of bacterial resistance. The kinetics in serum and urine and the clinical safety of a fixed combination of 4 g of piperacillin (PPR) and 0.5 g of tazobactam (TZB) were studied in 10 patients (22 to 50 years old and weighing 45 to 105 kg) with major burns who were infected with Pseudomonas aeruginosa and various enterobacteria. All of them received additional antimicrobial drugs. Treatment involved one dose every 6 h. The mean body surface area affected by third-degree burns was 30.0% ؎ 4.0%. The study took place in accordance with current ethical guidelines. Two series of blood samples were drawn after the first (day 1) and ninth (day 3 at steady state) doses; urine was collected during the same periods. Levels of PPR and TZB in serum and urine were measured by high-pressure liquid chromatography. A noncompartmental method was used for kinetic and graphic analysis of concentration-time pairs. The safety of the treatment was excellent. There was no systemic accumulation of the ␤-lactam combination. Residual concentrations measured on days 1 and 3 [mean (standard error of the mean)] were above the MIC for the organism responsible for infection; i.e., C min day1 ‫؍‬ 26.3 (8.5) and C min day3 ‫؍‬ 21.0 (9.1) for PPR and C min day1 ‫؍‬ 1.9 (0.6) and C min day3 ‫؍‬ 1.4 (0.3) for TZB. There was no statistically significant difference between pharmacokinetic parameters determined for day 1 and day 3. Evidence was found in burn patients, in contrast to healthy subjects, of a marked increase in apparent volumes of distribution, in such a way that the apparent elimination half-lives of the combination were notably prolonged, i.e., 1.8 (0.3) versus 1.5 (0.3) h for PPR in patients and healthy subjects, respectively, and 1.7 (0.3) versus 1.4 (0.3) h for TZB. These findings indicate the possibility of nonrenal translesional diffusion of PPR-TZB in burn patients. The polarity of the association would further support this hypothesis. It has been shown here that the recommended dosage regimen for administration of PPR-TZB must be high in major-burn patients, i.e., 4 g/0.5 g every 6 h. The data obtained provide valuable information, which is suitable for immediate application in everyday clinical practice.
The anti-infective strategy often required for patients with major burns is frequently complicated and applied in a complex and constantly changing pathophysiological context. The extreme metabolic attack often suffered by burn victims necessitates a powerful therapeutic strategy. However, for technical and ethical reasons, studies concerning the disposition of drugs administered to such subjects have been rare and their methodology has sometimes been questionable (3, 12, 15, 18, 22) . Diagnosis of an infectious syndrome in such patients is not always easy, since a nonspecific clinical picture of fever, hyperleukocytosis, and cutaneous, bronchial, or urinary multicolonization is often observed. Infection arises in a nosocomial context and requires broad-spectrum antibiotic therapy. Of the drugs used in this situation, ureidopenicillins, particularly piperacillin (PPR), are highly effective against enterobacteria and Pseudomonas aeruginosa and exhibit satisfactory safety. This is an important point, because patients are usually treated for a long time. However, the increasing incidence of resistance, notably through the production of ␤-lactamases, has frequently given rise to a reconsideration of the intrinsic efficacy of these therapies and to the assessment of novel drugs. For these reasons, piperacillin has recently been combined with a ␤-lactamase-inhibiting ␤-lactam, tazobactam (TZB) (Tazocilline, 4 g/0.5 g or 2 g/0.25 g in France, and Zosyn in the United States; Laboratoire Wyeth Lederle, St. Quentin Fallavier, France) (10) . Few studies have centered on the disposition of ␤-lactam antibiotics in burn patients. Reports on only ceftazidime (19) , imipenem (4) , and aztreonam (9) are available. Most of the data for the PPR-TZB combination were determined in healthy subjects (6, 20) . Consequently, extrapolation of these results to major-burn patients is difficult if not impossible.
In view of these points, it is important to refine our knowledge of the disposition of the PPR-TZB combination to better master its use in burn patients. A clinical kinetic study, including blood pharmacokinetics and urinary excretion of the combination, was undertaken in a pathophysiologically homogeneous population of major-burn subjects. The antibiotic combination was administered in a life-threatening context; thus, a high dosage was infused into our patients. Our results were compared with data obtained for healthy subjects and for another category of ill patients. Finally, the objective of this work was also to attempt to optimize the therapeutic regimen of the ␤-lactam combination.
MATERIALS AND METHODS
Subjects. Ten patients (eight men and two women) aged between 22 and 50 years and weighing between 45 and 105 kg, with a mean body surface area affected by third-degree burns of 30.0% Ϯ 4.0%, were included in this study. The percentage of the total body surface area that was burned was determined with a Lund and Browder chart (8) . Patients were hospitalized with signs of infection, characterized in particular by a temperature of Ն38.5ЊC and a leukocytosis of between 15,000 and 20,000 leukocytes per mm 3 . Patients with suspected or documented gram-negative infections including P. aeruginosa infections were eligible for study participation. Hepatic (especially aspartate aminotransferase and alanine aminotransferase levels) and renal (i.e., urea and creatinine concentrations and creatinine clearance) functions were in the normal range. Individual and mean (Ϯ standard error of the mean [SEM]) biometric parameters are given in Table 1 . It is important to point out that creatinine clearance was determined by timed evaluations of levels in urine. None of the subjects presented with a history of cystic fibrosis, an allergy to piperacillin and other ␤-lactams antibiotics, a history or evidence of alcoholic cirrhosis of the liver, or electrical burn injury, and none were undergoing any type of dialysis. Bacteriological specimens, i.e., blood cultures, bronchopulmonary and cutaneous specimens, and midstream urine, as well as a complete blood count, were obtained in all patients before starting treatment for infection. The following organisms were identified from blood cultures and cutaneous specimens: Escherichia coli (three cases), Proteus mirabilis (one case), Proteus vulgaris (three cases), Pseudomonas aeruginosa (five cases), Serratia marcescens (one case) and streptococci (three cases). This was an open, prospective, and nonrandomized study, with each patient serving as his or her own control.
Patients or close relatives were clearly informed and gave their written consent for two series of peripheral blood samples to be drawn during the treatment. Furthermore, urine fractions were also collected during each kinetic sequence. The study was conducted in accordance with the requirements of article L209-9 of the law dated 20 December 1988 concerning the protection of persons involved in biomedical research. Finally, this trial was approved by the Ethics Committees of the Cochin and Percy Hospitals (Paris and Clamart, respectively, France) in June 1993.
Design. The PPR-TZB combination was given on a curative basis, and other drugs, especially associated antimicrobial agents, were infused independently of the combination. Indeed, antibiotic therapy with drugs such as aminoglycosides or vancomycin and antifungals was also authorized (amikacin at 1.5 g/day in subjects 1, 2, 6, 7, 8, 9, and 10; teicoplanin at 800 mg/day in patient 8; vancomycin at 3 g/day in subjects 1, 2, 4, and 6; rifamycin at 1,800 mg/day in patient 4; amphotericin B at 150 mg/day in subject 3; and fluconazole at 200 mg/day in patient 10).
Dosing. The 10 subjects were given an infusion of 4 g-0.5 g of the ␤-lactam combination once every 6 h. In all cases, the combination was infused over 0.5 h through an electric syringe (slow intravenous push). The drugs were dissolved and diluted in 50 ml of glucose infusion (5%). Furthermore, the mean time between the initial burn insult and the administration of the first infusion was 12.4 Ϯ 1.4 days. Thus, in all cases, the antimicrobial treatments were administered during the hypermetabolic period.
Sample collection. During both the first (day 1) and second (day 3) periods of analysis, venous blood samples were drawn into dry tubes via a Cathlon catheter inserted into a vein on the contralateral side to the infusion. Two series of blood samples (5 ml per sample) were drawn after the first (day 1) and the ninth (day 3 at steady state) doses at time zero (immediately before the starting infusion) and 0.25, 0.50 (i.e., C max , at the end of infusion), 0.75, 1, 2, 3, 4, 5, and 6 h (i.e., C min , immediately before the beginning of the next infusion). The first analysis period enabled definition of the individual and initial pharmacokinetic behavior of PPR and TZB, while the aim of the second was to evaluate the fate of the antibiotic under steady-state conditions and in particular to assess any possible systemic accumulation. On day 2, two blood samples were drawn, at the end of the fifth infusion (C max 5) and before the sixth dose (C min 5). All blood samples were labelled and numbered, quickly taken to the laboratory, and centrifuged (at 2,000 ϫ g and 5ЊC for 10 min).
A baseline urine sample was obtained immediately prior to drug administration. To quantitate PPR-TZB urinary excretion, urine was collected over each sampling period. Since the patients were catheterized, four urine fractions were collected into dry tubes during each kinetic sequence, i.e., immediately before the first and the ninth infusions and then from 0 to 2 h, 2 to 4 h, and 4 to 6 h afterward. Urine was also collected for the 24 h immediately before or immediately following drug administration for creatinine clearance (CL CR ) measurement. All serum and urine samples for PPR-TZB concentration determinations were stored at Ϫ80ЊC (two tubes per sample) until the time of assay.
PPR and TZB assays. Samples (serum and urine) were assayed by highperformance liquid chromatography combined with UV spectrophotometric detection at 254 and at 220 nm for PPR and TZB, respectively. The technique used (ion-pair reversed-phase RP C-18 chromatography) complied with the analytical recommendations of Marunaka et al. (13) and Meulemans et al. (14) . PPR monohydrate and TZB were kindly provided by Wyeth Lederle Laboratories. The method used test specimens of 500 and 1,000 l of serum for PPR and TZB, respectively. The components were extracted with N,N-dimethylformamide and acetonitrile, respectively. Before extraction, urine was diluted (1/20) in 0.1 M phosphate buffer (pH 7). The lower limit of sensitivity was 0.5 mg/liter, while lower limits of quantification were 2 mg/liter for PPR and 0.5 mg/liter for TZB. The recoveries were 95% for the combination in serum and 97 and 94%, respectively, in urine. The accuracy of the assay method was studied at the target values of 10, 50, and 200 mg/liter for PPR and 1, 5, and 20 mg/liter for TZB (serum loaded with PPR or TZB in vitro); the coefficients of variation were 6, 2.6, and 2.25% for PPR and 1.1, 3.2, and 5.5% for TZB. The linear range of the assay was is the AUC during a 6-h dosing interval measured at steady state after the ninth infusion. R 1 is the predicted or theoretical accumulation ratio, and R 2 is the experimental value.
The method of superimposition was used to predict the concentration in serum after repeated administrations; concentrations in serum from the first dose of PPR-TZB were summed, and the concentrations from subsequent doses over time were predicted. The predicted levels were compared with the concentrations measured in serum after the repeated doses.
Monitoring of patients.
Clinical (temperature and the cardiac and respiratory rates) physical, and laboratory (specific quantification of hematologic values, biochemical specimens, and bacteriological specimens) monitoring was performed daily from the first day to the last day of treatment.
Local and systemic tolerability-treatment efficacy. Although our aim was to study the disposition of a ␤-lactam combination, the bacteriological efficacy of the treatment was also assessed by studying the reduction in CFU present in cultures, the regression of pyrexia, and the normalization of blood count. Patients were not questioned about adverse effects during infusion, but the systemic tolerability of treatment was monitored regularly (repeated clinical and laboratory assessments).
Statistical analysis. All results are expressed as means Ϯ SEM. Each patient was taken as his or her own control, and kinetic data obtained from each period of analysis were compared by the Wilcoxon t test. Linear regression, by using the method of least squares, was used to assess relationships between pharmacokinetic parameters and biological and morphometric data, with statistical significance determined by the F test. P Յ 0.05 was considered to be statistically significant. The percentage of PPR and TZB excreted in urine was calculated as (amount of PPR or TZB recovered in the urine/administered intravenous dose) ϫ 100. Finally, mean pharmacokinetic results obtained after the first dose of ␤-lactams were compared with the data obtained for healthy subjects (6, 20) and those for surgical patients (11) .
RESULTS
The mean duration of treatment was 14.6 Ϯ 2 days. Systemic tolerability was good, and no adverse events imputable to the combination were recorded. A gastroenteritis possibly linked to the treatment was seen in subject no. 5; however, this adverse event regressed spontaneously (in 48 h) during the treatment. Bacteriological tests performed on 8 patients at the end of treatment demonstrated the disappearance of the pathogens incriminated in the infection. Figure 1 compares the evolution of PPR and TZB concentrations in serum after the first PPR-TZB infusion and at steady state. If taken in pairs, the tracings were similar, and although the dosage had not been adjusted to body weight, interindividual variability was very small. Indeed, the mean (SEM) dose administered to all patients was 57.93/ 7.24 (27.79/3.09) mg/kg of actual body weight. The pharmacokinetic parameters for all patients studied following the first and ninth doses are shown in Tables 2 to 5. Table 6 provides a synoptic comparison of mean kinetic markers characterized on day 1 and then at steady state. The lack of any statistically significant differences between parameters on days 1 and 3 was confirmed, including theoretical (R 1 ) and experimental (R 2 ) accumulation ratios; i.e., R 1 ϭ 1.13 (0.04) and R 2 ϭ 1.23 (0.09) for PPR, and R 1 ϭ 1.15 (0.06) and R 2 ϭ 1.30 (0.11) for TZB. Figure 2 shows a kinetic model constructed on the basis of mean initial profiles (on day 1). Application of a 4-g/0.5-g algorithm and ϭ 6 h revealed excellent coincidence between the experimental points measured both on day 3 and at the two intermediate analytical points (C max 5 ϭ 319.7 [39.8] and C min 5 ϭ 32.6 [11.1] for PPR, and C max 5 ϭ 23.2 [1.7] and C min 5 ϭ 1.6 [0.6] for TZB) and the predictive profile. PPR and TZB were rapidly excreted in urine, and the quantities found during the initial 6-h dosing interval were large, i.e., 51.9 (4.5%) and 63.6% (8.8%) for PPR and TZB, respectively, corresponding to a renal clearance of 75.9 (16.2) and 157.4 (28.2) ml/min, respectively; once more, the limited dispersion of results should be emphasized. Overall, the metabolic behavior of the ␤-lactam combination in major-burn patients appeared to be very stable. Total clearances of PPR and TZB were correlated with urea levels in serum, (r ϭ 0.67 and P ϭ 0.03, and r ϭ 0.56 and P ϭ 0.08, respectively) and, on the other hand, with the CL CR (r ϭ 0.83 and P ϭ 0.03, and r ϭ 0.72 and P ϭ 0.02, respectively). Furthermore, the CL R of PPR was significantly correlated with both urea concentration in serum and CL CR (r ϭ 0.67 and P ϭ 0.03, and r ϭ 0.82 and P ϭ 0.004, respectively).
DISCUSSION
The severity of the pathophysiological status of major-burn patients makes it difficult to undertake any studies in this area. Although ethical requirements must be strictly respected, it should be emphasized that such work cannot be undertaken unless the treatment is considered necessary and likely to provide novel solutions or therapeutic alternatives.
The clinical and bacteriological efficacy of the PPR-TZB combination was stable, and no major adverse events were noted. Overall, with the dosage regimen used, both PPR and TZB kinetics in major-burn subjects were also remarkably stable. This kind of behavior has been reported for other categories of antibiotics and patients, notably with aminoglycosides, ceftazidime, and aztreonam (9, 15, 19, 22) . These products share high polarity and a weak or null metabolism. These elements contribute to our understanding of the limited interindividual variability observed. In terms of efficacy, the timedependent antibiotic combination studied demonstrated mean C min levels at day 1, day 3, and an intermediate period which were higher than the MIC for the microorganisms implicated (which have been established as being susceptible to the combination [1] ), i.e., less than 8 and 16 mg/liter for members of the family Enterobacteriaceae and P. aeruginosa, respectively. Consequently, the chosen therapeutic regimen was seen to be satisfactory and we were able to confirm a posteriori the choice of a modified, increased dosage regimen in major-burn patients when compared with the usual schedule.
Similar to the results reported by Walstad et al. (19) and Friedrich et al. (9), we noted changes in the volume of distribution of the ␤-lactam combination in burn patients. Comparison of our results (on day 1) with those found by Cheung et al. (6) (PPR and TZB also assayed by high-performance liquid chromatography methods) in six healthy volunteers who received a single 4-g/0.5-g dose demonstrated an important increase of the V ss values for the combination in our patients while the CL of PPR decrease in burn patients led to a increased AUC (by a factor of about 2) (6). In contrast, AUCs were similar for TZB (Table 6 ). Finally, in both cases, the proportionally higher increases in V ss explain the longer t 1/2␤ s of the combination in burn patients (by a factor of about 3 and 2 for PPR and TZB, respectively). Burn injury is known to result in decreased albumin concentrations in serum. However, in the present case, total protein and albumin concentrations (20) . In their work, they studied the urinary excretion of the combination (first 6-h period), and their results are closely similar to our own data, i.e., 51.9% (4.5%) versus 49.8% (4.7%) and 63.6% (8.8%) versus 56.8% (2.7%) excreted in urine for PPR and TZB, respectively. Thus, urinary excretion of the PPR-TZB combination seems not to be affected by the pathophysiological status of the patients. Kinzig et al. treated 18 patients in the context of colorectal surgery; kinetic analysis was performed at the steady state (fifth dose) (11) . It appears that compared with healthy subjects, the trends already suggested were of the same order of magnitude. These results confirm the need for an in situ study of drug metabolism in the case of severe pathological situations. PPR-TZB disposition in burn patients is altered as a result of thermal injury, with the major effect being an increase in the apparent volumes of distribution. Moreover, CL R s did not appear to be affected and CL remained associated with both clearance of creatinine and urea concentration in serum. The pharmacokinetic modifications observed in burn patients cannot be attributed to an increase in urinary clearance, although such patients were multiperfused. The pathophysiological hypothesis we put forward is as follows: abolition, in terms of surface and volume, of a major proportion of membrane barriers and peripheral tissues (skin and fatty panicles), a prolonged systemic inflammatory state (shock and edemas through a reduction in membrane permeability), and the presence of profound metabolic stress combine to give rise to the massive production of exudates and to heat loss, the vector for which consists of interstitial fluids. It is reasonable to suggest that in burn patients, the diffusion of high-polarity drugs such as PPR and TZB is intense. The possibility of a nonrenal and nonbiliary clearance, which could be called translesional, may be indicated by these findings. This explanation has also been suggested by Potel et al. for fosfomycin in five burn patients; it could constitute a cofactor in terms of the success of treatment (16) . Of course, concentrations of PPR and TZB in tissue should be measured in the future in order to support this hypothesis.
Knowledge of the metabolic characterization of powerful therapies is essential in major-burn patients, as in those with other severe conditions (e.g., multiple trauma, disease during pregnancy, and cystic fibrosis). In our opinion, the data collected during this work provide valuable information which can be applied immediately in daily clinical practice. In summary, we found that (i) the pharmacokinetic behavior of the PPR-TZB combination appeared to be altered in patients with major thermal injury when compared with healthy subjects; (ii) the kinetic changes observed suggest the possible existence of a translesional diffusion of the combination; (iii) there was no accumulation or metabolic acceleration, and the C min values found on day 1 and at plateau were above the MIC for the pathogens isolated; and (iv) the dosage regimen chosen for PPR-TZB, i.e., 4 g/0.5 g every 6 h, was satisfactory in terms of safety. Finally, this study contributes to improving the prognosis and the treatment for some of the major infectious diseases experienced by severely burned patients.
